A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B
Public ClinicalTrials.gov record NCT00116805. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B
Study identification
- NCT ID
- NCT00116805
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Gilead Sciences
- Industry
- Enrollment
- 266 participants
Conditions and interventions
Conditions
Interventions
- TDF Drug
- ADV Drug
- TDF placebo Drug
- ADV placebo Drug
- FTC/TDF Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 69 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2005
- Primary completion
- Apr 30, 2007
- Completion
- Dec 31, 2015
- Last update posted
- Mar 8, 2017
2005 – 2016
United States locations
- U.S. sites
- 20
- U.S. states
- 10
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Orange | California | 92868 | — |
| Not listed | Pasadena | California | 91105 | — |
| Not listed | San Diego | California | 92105 | — |
| Not listed | San Jose | California | 95116 | — |
| Not listed | Miami | Florida | 33136 | — |
| Not listed | Atlanta | Georgia | 30308 | — |
| Not listed | Atlanta | Georgia | 30309 | — |
| Not listed | Honolulu | Hawaii | 96817 | — |
| Not listed | Baltimore | Maryland | 21229 | — |
| Not listed | Ann Arbor | Michigan | 48109 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | St Louis | Missouri | 63104 | — |
| Not listed | Flushing | New York | 11355 | — |
| Not listed | New York | New York | 10021 | — |
| Not listed | New York | New York | 10029 | — |
| Not listed | New York | New York | 10032 | — |
| Not listed | Fairfax | Virginia | 22031 | — |
| Not listed | Falls Church | Virginia | 22042 | — |
| Not listed | Richmond | Virginia | 23298 | — |
| Not listed | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00116805, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 8, 2017 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00116805 live on ClinicalTrials.gov.